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ABSTRACT                                                                             
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis 
of skin and numerous internal organs and a severe fibroproliferative vasculopathy resulting 
frequently in severe disability and high mortality. Although the etiology of SSc is unknown and 
the detailed mechanisms responsible for the fibrotic process have not been fully elucidated one 
important observation from a large U.S. population study was the demonstration of a late onset 
of SSc with a peak incidence between 45 and 54 years of age in African-American females and 
between 65 and 74 years of age in white females. Although it is not appropriate to consider SSc 
as a disease of aging, the possibility that senescence changes in the cellular elements responsible 
for its development may play a role has not been thoroughly examined. The process of cellular 
senescence is extremely complex and the mechanisms, molecular events, and signaling pathways 
involved have not been fully elucidated, however, there is strong evidence to support the concept 
that oxidative stress caused by the excessive generation of reactive oxygen species may be one 
important mechanism involved. On the other hand, numerous studies have implicated oxidative 
stress in SSc pathogenesis, thus, suggesting a plausible mechanism in which excessive oxidative 
stress induces cellular senescence and that the molecular events associated with this complex 
process play an important role  in the fibrotic and fibroproliferative vasculopathy characteristic 
of SSc. Here, recent studies examining the role of cellular senescence and of oxidative stress in 
SSc pathogenesis will be reviewed.  
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INTRODUCTION                                                             
Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology characterized 
by progressive fibrosis of skin and numerous internal organs and a severe fibroproliferative 
vasculopathy resulting frequently in functional disability and high mortality [1-3]. The 
pathogenesis of SSc is complex and despite numerous studies that have examined its intricate 
picture, the exact mechanisms involved in the severe cutaneous and systemic fibrotic process 
have not been fully elucidated [4-7]. One important demographic feature identified in a large SSc 
population is that SSc disease onset and its peak incidence occur between the ages of 45 and 54 
years for African American women and between the ages of 65 and 74 years for white women 
[8]. The reasons for the late onset and higher frequency of SSc in individuals older than 45 years 
of age are not known and have not been examined in detail. Although it is not appropriate to 
consider SSc as a disease of aging, the possible role of cellular senescence in SSc pathogenesis 
should be considered as an important factor. Among the reactions or pathways that may be 
involved in this process there is strong evidence that oxidative stress mediated by an excessive 
generation of reactive oxygen species (ROS) plays a crucial role. We will review here recent 
experimental evidence supporting the participation of cellular senescence and oxidative stress in 
SSc pathogenesis emphasizing the potential role of oxidative stress in the fibrotic process that is 
the hallmark of SSc. We will also discuss recent evidence indicating that the NADPH oxidase 
NOX4 may be one of the most important mediators of ROS generation in SSc, and the 
potentially beneficial effects of inhibition of NOX4 activity as a cogent therapeutic approach for 
SSc-associated tissue fibrosis and fibroproliferative vasculopathy. 
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CELLULAR SENESCENCE AND SSc PATHOGENESIS. 
Cellular Senescence and Senescence Associated Secretory Phenotype.  
Cellular senescence, a process first identified by Hayflick and Moorehead in their pioneering 
studies on human diploid fibroblasts cultured in vitro [9,10], is characterized by the permanent 
arrest of cell division associated with a variety of phenotypic changes including cellular 
enlargement, flattening, and vacuolization, as well as, numerous functional alterations [Reviewed 
in 11-16]. The most prominent of these alterations are the expression of novel specific gene 
products such as the senescence-associated β-galactosidase isoform (SA-β gal), and the 
acquisition of a unique complement of secreted molecules which includes inflammatory 
cytokines and chemokines, growth factors, and various proteases and other pro-inflammatory 
molecules collectively known as the senescence-associated secretory phenotype or SASP [17**-
21]. The most important pro-inflammatory and pro-fibrotic SASP components are listed in Table 
1. Although it was initially considered that cellular senescence may be solely a protective 
mechanism to prevent the uncontrolled cellular proliferative activity of malignant cells, extensive 
studies have demonstrated that it may participate in numerous physiological processes including 
embryonic development [22**,23**], as well as in pathologic conditions associated with aging 
[11-13, 24,25]. 
The mechanisms responsible for the irreversible arrest in cellular proliferative capacity are 
highly complex and although they have been studied extensively, they have not been fully 
elucidated. However, it has been shown that a variety of stimuli and numerous signaling 
pathways may be involved [11-13, 16,18]. The most important triggers of cellular senescence are 
the activation of the DNA-damage response (DDR) initiated by the occurrence of structural 
changes in DNA and complex molecular events involving oncogene effects, abnormalities in cell 
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cycle kinases, including various cyclin-dependent kinases, and telomere shortening or 
dysfunction [11-13, 26-28]. Of relevance to the topic of this review are the extensive 
observations demonstrating that two important mechanisms involved in cellular senescence are 
reactive oxygen species (ROS)-induced oxidative stress [29-34] and persistent stimulation by 
type I interferons [35-37]. 
 Cellular Senescence and SSc.  
There has been strong interest in the role of cellular senescence in malignancies and disorders of 
aging, however, there is very little information about its possible contribution to SSc 
pathogenesis. Among the few investigations that have explored the possible connection between 
senescence, aging, and SSc, a recent study conducted an evaluation of normal fibroblasts 
obtained from donors of various ages (up to 33 years of age) and of several dermal fibroblast cell 
strains obtained from patients with SSc employing a proteomic approach [38**]. The study 
identified numerous age-dependent differences including the accumulation of SA-βgal and 
showed that SSc fibroblasts displayed evidence indicative of cellular senescence and decreased 
autophagy. Another study [39] examined bone marrow derived mesenchymal stem cells from 
SSc patients and demonstrated that these cells displayed markers of early senescence and had an 
impairment in their ability to differentiate into endothelial cells suggesting that these alterations 
may be important for the pathogenesis of the vascular involvement in SSc.  
Numerous studies have examined alterations in telomere length as playing a role in the 
development of various autoimmune diseases including rheumatoid arthritis, systemic lupus 
erythematosus, SSc, and Sjögren syndrome, however, the available evidence is not conclusive 
and may be even contradictory in some studies [40,41]. There are very few studies of telomere 
length in SSc [42-44]. Although an early study described that telomere length was significantly 
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shortened in SSc patients and suggested that this observation may be either reflective of a genetic 
predisposition to chromosomal instability or the result of exposure to a noxious environmental 
agent [42], a more recent study described contradictory results demonstrating that telomere 
length was longer in peripheral blood mononuclear cells from SSc patients [44]. Therefore, the 
original description of shortened telomeres in cells from SSc patients requires further 
experimental validation. In this respect, a study of telomerase activity in peripheral blood 
mononuclear cells from patients with various autoimmune diseases demonstrated that in contrast 
with cells from patients with rheumatoid arthritis and systemic lupus erythematosus that 
displayed elevated activity of the enzyme, cells from SSc patients had remarkably low levels of 
telomerase activity [45]. However, the significance of this observation to SSc pathogenesis has 
not been elucidated. 
Although not directly related to SSc pathogenesis, several studies of another fibrotic disease that 
displays a clear pattern of increased occurrence in older individuals; namely idiopathic 
pulmonary fibrosis (IPF), have provided evidence to support the notion that cellular senescence 
may play an important role in its pathogenesis [46-48]. Indeed, recent studies showed an 
unexpectedly high frequency of telomerase mutations and telomere shortening in a large 
population of patients affected with the familial form of IPF [49,50]. 
Caveolin-1 and PTEN in cellular senescence.  
Strong experimental evidence has demonstrated that caveolin-1 (cav-1), the protein responsible 
for the remarkable functional properties of caveolae, is decreased in affected cells and tissues 
from SSc or IPF patients [51-54]. Numerous recent studies have shown that cav-1 plays and 
important role in the pathophysiology of tissue fibrosis [51,52,55**]  most likely, owing to its 
ability to induce internalization of activated TGF-β receptors into cav-1 lipid rafts leading to 
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their rapid proteasomal degradation [52,55**]. Although an earlier study indicated that 
expression of cav-1 induced premature cellular senescence in primary cultures of murine 
fibroblasts [56], and a more recent investigation demonstrated that cav-1 deficiency protects 
from bleomycin-induced pulmonary fibrosis in mice [57], recent evidence indicates that cav-1 
exerts antifibrotic effects by modulating the activity of the phosphatase and tensin homolog 
(PTEN). PTEN is a tumor suppressor protein that has been implicated in cellular senescence. A 
recent study found that PTEN was markedly decreased in lung fibroblasts from IPF patients as 
well as in lungs from mice with bleomycin-induced pulmonary fibrosis and that this reduction 
was mediated by decreased cav-1 [58]. In light of previous studies demonstrating that a reduction 
of PTEN exerted potent pro-fibrotic effects in vitro and in vivo [59], the newly uncovered 
interaction between cav-1, PTEN and cellular senescence represents a novel pro-fibrotic 
mechanism that may be of relevance to SSc pathogenesis. 
ROS and OXIDATIVE STRESS IN SSc PATHOGENESIS. 
Evidence of oxidative stress in SSc.   
In 1993, Murrell proposed a unifying hypothesis to explain the pathogenesis of the cutaneous 
fibrotic process in a variety of systemic fibrotic disorders including SSc suggesting a crucial role 
for oxygen free radical induced oxidative stress [60]. Following this report numerous studies 
have provided experimental support for this hypothesis and explored the mechanisms involved 
[Reviewed in 61- 63]. It has been shown that oxidative stress in SSc is the result of an imbalance 
between the production of oxidative stress producing systems and their antagonist antioxidant 
mechanisms. Increased generation or overproduction of ROS appears to be the main mechanism 
whereas ROS inactivation plays a less important role. Although one recent study demonstrated 
increased levels of antioxidants in serum of about 25% of SSc patients as measured by a total 
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antioxidant power assay [64**], numerous other studies have shown increased ROS production 
by various cells in SSc, as well as elevated levels in plasma from SSc patients [65*-69] 
providing strong evidence for the important contribution of oxidative stress in SSc pathogenesis. 
A recent study compared the total oxidant status (TOS), total antioxidant status (TAS) and an 
oxidative stress index (OSI) between SSc patients and healthy volunteers. The results 
demonstrated that TOS and OSI levels were significantly higher in SSc patients than in controls, 
whereas there were no significant differences in TAS between the two groups [65**]. These 
results indicated a remarkable imbalance between the profoundly increased oxidative stress 
levels and the relatively insufficient antioxidant status in SSc. In agreement with these 
observations elevated levels of various oxidative stress-related products have been detected in 
various biological fluids from SSc patients including increased urinary 8-oxodG levels [70], and 
increased levels of isoprostanes  in SSc serum [71,72], in the urine [73,74] or in exhaled breath 
[75].  Isoprostanes such as F2-isoprostanes are markers of lipid peroxidation [76], produced in 
vivo in humans by free radical-catalyzed peroxidation of arachidonic acid. Other markers of 
oxidative stress in SSc include increased serum levels of N(epsilon)-(hexanoyl)lysine [77] and 
elevated serum levels of heat shock protein 70 [78]. The functional relevance of the elevated 
oxidative stress components in the circulation of SSc patients was evidenced in one recent study 
showing that sera from patients with SSc pulmonary hypertension caused oxidative stress 
induced activation of collagen synthesis in human pulmonary smooth muscle cells [79]. 
Role of ROS in SSc fibrosis and fibroproliferative vasculopathy.   
ROS are a group of oxygen-derived molecules characterized by high chemical reactivity. It has 
been recently recognized that under physiological conditions ROS play important functions in 
intracellular signaling by activating redox-sensitive pathways including the cellular responses to 
 9 
 
growth factor stimulation and the establishment of inflammatory responses [Reviewed in 80-82]. 
However, in pathological states, higher ROS levels can induce oxidative stress causing damage 
to proteins, lipids, and DNA, as well as inducing cellular senescence as discussed above.  
Following Murrell’s provocative hypothesis linking SSc pathogenesis to the deleterious effects 
of ROS [60] numerous studies have implicated excessive oxidative stress and the generation of 
deleterious ROS in the pathogenesis of SSc [Reviewed in 61-63]. The studies of Sambo et al. 
[69] provided elegant experimental evidence that SSc dermal fibroblasts produce increased 
levels of ROS compared with normal cells and that the elevated ROS may be involved in the 
increased expression of a profibrotic phenotype in these cells. The same group also demonstrated 
that monocytes from SSc patients spontaneously release increased amounts of superoxide anion 
in vitro [66].  Other studies supporting the role of ROS in the development of the fibrotic and 
vasculo-proliferative lesions in SSc include the induction of high production of ROS by 
endothelial cells and fibroblasts in vitro following exposure to sera from SSc patients [68] and in 
pulmonary artery smooth muscle cells exposed to serum from SSc patients with pulmonary 
hypertension [79], as well as the ROS mediated inhibition of the anti-Wnt protein, Wint 
inhibitory factor 1 (WIF-1) leading to activation of Wnt pathway-induced tissue fibrosis (83**). 
Another study described a dose dependent abrogation of the increased production and secretion 
of type I collagen and fibronectin characteristic of SSc fibroblasts following in vitro exposure to 
the potent antioxidant, epigallocatechin-3-gallate (EGCG). EGCG also reduced the expression of 
the fibrotic marker CTGF, inhibited collagen gel contraction, and suppressed intracellular 
ERK1/2 kinase signalling and NF-κB activity [84**].  
Although the detailed mechanisms involved in ROS effects in induction and establishment of the 
fibrotic process in SSc have not been fully elucidated there is intense ongoing research exploring 
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various novel directions. Among these, one recent study described a novel mechanism by which 
ROS may promote a profibrotic phenotype in SSc fibroblasts [85**]. This mechanism involves 
the ROS-mediated oxidative inactivation of protein tyrosine phosphatase 1B (PTP1B) leading to 
pronounced platelet derived growth factor receptor (PDGFR) activation. In this study, PTP1B 
activity was significantly reduced in SSc fibroblasts, most likely as a result of increased cysteine 
oxidation caused by higher levels of ROS. Confirmation of the important role of PTP1B on the 
regulation of the fibrotic process was obtained from studies showing that decreased PTP1B 
expression in normal fibroblasts led to increased expression of the genes encoding type I 
collagen and to elevated production of the corresponding protein [85**].  
NADPH OXIDASES (NOX). 
The NOX family of membrane-associated enzymes catalyze the reduction of O2 to form ROS. 
The crucial roles of NOX in normal cellular physiology is evidenced by the remarkable increase 
in the number of NOX isoforms during eukaryotic evolution and their striking conservation 
through multiple species [86,87]. Several biochemical processes and enzyme systems are capable 
of producing ROS in vivo, however, the NADPH oxidases are the primary enzymes responsible 
for inducible ROS formation [Reviewed in 88-90]. The role of NOX enzymes in a variety of 
human disorders is currently the focus of intense investigation and numerous studies have 
provided strong experimental evidence to support their participation in a variety of pathologic 
conditions. Currently seven distinct NOX isoforms have been identified in humans and there are 
substantial differences in their tissue distribution, however, several of them display prominent 
expression in tissues and cells of substantial relevance to the pathophysiology of SSc. The three 
most important NOX isoforms related to SSc are NOX1, NOX2, and NOX4. Although the 
highest expression levels of NOX1 are in colonic epithelium, this isoform is also abundantly 
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expressed in endothelial cells and vascular smooth muscle cells. NOX2 is the classic 
inflammatory isoform found in neutrophils and macrophages but is also expressed in B-
lymphocytes and in endothelial cells. NOX4 is highly expressed in the kidneys, however, it 
displays very high expression in fibroblasts, smooth muscle cells, and endothelial cells as well as 
in the lung.  
ROLE OF NOX4 IN TISSUE FIBROSIS 
 Numerous recent studies have shown that NOX4 is a crucial molecule involved in the initiation, 
establishment and development of tissue fibrosis.  Indeed, multiple growth factors and related 
polypeptides which participate in SSc pathogenesis [4-7] including TGF-ß, the most potent 
cytokine implicated in the fibrotic process, as well as other profibrotic polypeptides including 
PDGF, angiotensin II, and endothelin-1 have been shown to modulate the expression of NOX, 
and in particular, that of NOX4. Stimulation of NOX4 expression by TGF-β has been 
demonstrated in numerous recent studies [91-93]. PDGF, angiotensin II, and endothelin-1 have 
also been shown to induce increased NOX4 expression [94-96]. NOX4 has been identified as a 
source of ROS responsible for the generation and activation of TGF-β induced pulmonary, 
cardiac and renal myofibroblasts in vitro [91-93, 97-102]. NOX4 is upregulated in lungs of 
patients with IPF and in kidney and liver fibrosis [99,103,104]. NOX4-dependent generation of 
ROS has been postulated to be involved in the fibrotic process in SSc [105,106], however, 
experimental evidence in support of this hypothesis is still lacking. Of great relevance to the role 
of NOX4 in the pathogenesis of the fibroproliferative vasculopathy in SSc is a recent study 
demonstrating that ROS were capable of inducing the phenotypic conversion of endothelial cells 
into activated myofibroblasts through a TGF-β dependent mechanism [107**]. 
Regulation of NOX4 activity.  
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The mechanisms involved in the regulation of NOX activity are quite complex and it is likely 
that they vary depending on a specific cellular and functional context. However, it is important to 
emphasize that, in contrast with all other NOX enzymes, NOX4 does not require other protein 
subunits for its activity and, therefore, the levels of its activity are dependent on the levels of 
expression of its corresponding gene [108]. Given the important functions of NOX4 in a variety 
of physiological processes and in the pathogenesis of numerous diseases, there has been intense 
interest in unveiling the intimate mechanisms of its regulation. The mechanisms of increased 
NOX4 expression by TGF-β are the focus of intense investigation [109,110]. A recent study 
identified a far upstream AP-1/Smad binding element in the human NOX4 promoter that was 
involved in the regulation of NOX4 expression by TGF-β [109].  
Regarding the regulation of NOX4 activity one important mechanism has been recently 
recognized. This study demonstrated a novel and quite important interaction of NOX4 with the 
polymerase delta interacting protein 2 (PDIP2) that resulted in a three-fold stimulation of NOX4 
activity by PDIP2 [111**]. The full significance of this important discovery is still not apparent 
but undoubtedly represents a promising novel area for further investigation. Although the exact 
mechanisms involved in the regulation of NOX4 levels in normal cells are becoming unveiled 
the possible alterations responsible for the constitutive elevation in NOX4 levels and activity in 
SSc cells have not been studied.  
NOX4 inhibitors as a potential antifibrotic therapeutic intervention.   
Following Murrell’s provocative hypothesis [60], numerous studies have provided strong 
supporting evidence for a role of ROS in abnormal, exaggerated fibrogenesis, and for the 
therapeutic targeting of ROS in fibrotic disorders such as SSc [112]. Indeed, a plethora of 
clinical studies have examined a variety of pharmacological or naturally occurring antioxidant 
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compounds as potential therapeutic agents for various aspects of the complex clinical 
manifestations of SSc [113-122]. Most of the clinical studies examining the effects of antioxidant 
therapy for SSc including some large placebo controlled clinical trials [122] have not provided 
conclusive evidence of a therapeutical benefit. However, the recent demonstration of the crucial 
role of NOX4 in the generation of ROS and the development of highly selective small molecule 
inhibitors [123**,124**] and/or specific small synthetic peptide inhibitors targeting NOX4 
[125**] offers substantial promise for the treatment of currently incurable fibrotic disorders, 
such SSc or IPF [Reviewed in 126-128]. Indeed, numerous recent studies have shown that a 
selective NOX1/NOX4 inhibitor exerted highly effective antifibrotic effect in various animal 
models of tissue fibrosis [129-132]. The extensive study of Hecker et al. (131**) demonstrated 
remarkable differences in the extent and severity of bleomycin-induced pulmonary fibrosis 
induced in young mice compared to aged mice. These differences were caused by a NOX4-
induced senescence phenotype in fibroblasts from the aged animals that prevented fibrosis 
resolution by rendering these cells resistant to apoptosis. The results demonstrated that persistent 
lung fibrosis in aging was mediated by NOX4 induced oxidative stress that resulted in cellular 
senescence and the acquisition of an apoptosis-resistant fibroblast phenotype. A remarkable 
observation was the reversal of these phenotype following treatment with the NOX4 selective 
small molecule inhibitor, GKT137831. 
Although the extensive investigational studies reviewed above have suggested that specific or 
selective NOX4 inhibitors may be of benefit for the therapy of SSc patients their beneficial 
effects need to be conclusively demonstrated in rigorously controlled clinical trials. 
CELLULAR SENESCENCE AND OXIDATIVE STRESS PATHWAYS LEADING TO 
TISSUE FIBROSIS IN SSc. 
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The causative agent or events and the exact mechanisms responsible for SSc development 
remain unknown. However, extensive recent information about cellular senescence and oxidative 
stress suggest a cogent hypothesis that may explain numerous observations obtained from the 
study of SSc cells and tissues. This hypothesis postulates that the potent profibrogenic growth 
factor, TGF-β becomes activated following its release from the TGF-β latent binding protein and 
engages its cognate receptors in the surface of TGF-β-responsible cells. The sequence of events 
resulting from active TGF-β receptor engagement leads to the upregulation of expression of 
NOX4 mediated by the canonical Smad pathway although other non-canonical TGF-β signaling 
pathways may be involved as well. Owing to the fact that NOX4 does not require additional co-
factors and that its activity is largely determined by the levels of protein expression, the TGF-β 
induced increase in NOX4 transcript levels results in increased NOX4-mediated ROS 
production. Elevated ROS production would then initiate a cascade of events leading to the 
establishment of an autocrine and paracrine self-stimulating pathway responsible for the 
progressive fibrotic process in SSc. The main components of the autocrine/paracrine loop 
induced by elevated ROS levels include the following:  
1. Further release of TGF-β from the latent TGF-β complex.   
2. Intracellular activation of TGF-β-dependent signaling pathways leading to the activation 
of quiescent fibroblasts and the induction of the myofibroblast phenotype in these cells, 
as well as in endothelial cells through the process of endothelial to mesenchymal 
transition. The activated myofibroblasts are the cells ultimately responsible for the 
fibrotic process in SSc. TGF-β also causes downregulation of genes encoding for 
antifibrotic proteins such as cav-1 and PTEN or MMPs and other ECM degrading 
 15 
 
enzymes. Reduction of cav-1 and PTEN is also involved in stimulation of cellular 
senescence as well as in stimulation of the pro-fibrotic phenotype. 
3. ROS-mediated initiation and maintenance of cellular senescence. This is one of the 
crucial components of the pathway initiated by ROS-mediated oxidative stress in the 
target cells that results in tissue fibrosis. Although other mechanisms that cause cellular 
senescence such as DDR or telomere shortening may also be involved, oxidative stress, 
an important initiating event of cellular senescence is induced by elevated ROS levels.  
4. The establishment of cell senescence in the target cells is accompanied by profound 
structural and molecular changes including the expression of SASP and the secretion of 
multiple proinflammatory and profibrotic molecules (Table 1). 
5. The multiple components of the SASP exert potent effects on a variety of cells that are 
involved in SSc pathogenesis including fibroblasts, endothelial cells and monocytes. 
6. Cytokines and growth factors present in the SASP induce quiescent fibroblasts to become 
activated and to acquire the profibrotic phenotype of activated myofibroblasts. These 
cells produce exaggerated levels of various ECM macromolecular components and, also 
display reduced expression and secretion of relevant metalloproteinases and other 
proteases capable of degradation of ECM components. 
7. The endothelial cells present in the microvasculature in proximity to the senescent cells 
are also induced by SASP components to change their phenotype and become activated 
myofibroblasts through endothelial to mesenchymal cellular transdifferentiation 
processes. 
8. Monocytes are attracted from the circulation through the effects of various cytokines and 
chemokines present in the SASP and become activated. Following their activation 
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macrophages are induced to change their phenotype into profibrotic M2 macrophages 
which then establish a chronic inflammatory infiltrate in the affected tissues.  
9. The activated M2 macrophages can directly contribute to the fibrotic process through the 
production and secretion of profibrotic cytokines and growth factors causing further 
stimulation of ECM production as well as, by enhancing the activation of quiescent 
fibroblasts into myofibroblasts and by inducing the endothelial to mesenchymal transition 
of endothelial cells. 
10. The activated macrophages also contribute to the establishment of a vicious cycle 
mediated by the macrophage production of TGF-β, and interferons and related 
macromolecules. The macrophage production of TGF-β can induce further NOX4 
production, and the interferon and related peptides can re-enforce the process of cellular 
senescence, thus allowing the establishment of an autocrine and paracrine self-sustaining 
mechanism that leads to tissue fibrosis. 
 
CONCLUSION 
 There is strong experimental evidence supporting the concept that cellular senescence and ROS-
mediated oxidative stress play a crucial role in the initiation, establishment and the progression 
of fibrosis in SSc and that these effects appear to involve NOX4. Therefore, the potential use of 
specific NOX4 inhibitors for the treatment of SSc would be expected to be an effective 
therapeutic approach. Although numerous clinical studies have examined the potentially 
beneficial effects of various therapeutic interventions aimed at the reduction of oxidative stress 
for SSc the results have not conclusively shown therapeutic effectiveness. Therefore, it will be 
necessary to perform in vitro studies with specific or selective small molecule or peptide NOX4 
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inhibitors followed by well designed placebo controlled clinical trials to document conclusively 
any beneficial effects. Furthermore, clinical trials should also consider evaluating the use of 
NOX4 inhibitors in combination with other drugs modulating different  pathways of the complex 
pathogenesis of SSc as this multidrug approach may result in improved therapy for this disabling 
and frequently fatal disease. 
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Legend to Figures. 
Figure 1.  Schematic diagram depicting the mechanisms involved in the induction of 
SSc-associated tissue fibrosis by cellular senescence and ROS-mediated oxidative stress 
and in the establishment of an autocrine/paracrine vicious cycle responsible for the 
progression and persistence of the fibrotic process. 1. Release of TGF-β from the latent 
TGF-β binding protein, followed by its activation and binding to cognate TGF-β 
receptors. 2. Stimulation of transcription of the NOX4 gene leading to increased NOX4 
and to increased ROS production. 3. Elevated ROS levels induce oxidative stress in the 
target cells as well as phenotypic changes in fibroblasts and endothelial cells causing 
their conversion into activated myofibroblasts. 4. Oxidative stress induces 
morphological and functional changes of cellular senescence. 5. Senescent cells express 
the senescence-associated secretory phenotype (SASP). 6-9.The components of the 
SASP induce phenotypic changes in fibroblasts (6), endothelial cells (7) and monocytes 
(8). The monocytes become activated M2 profibrotic macrophages that further increase 
the fibrotic process (9). 10. The activated macrophages produce and secrete TGF-β and 
interferons and various interferon-related molecules. The secreted TGF-β and 
interferon related products close the vicious cycle and allow establishment of an 
autocrine/paracrine pathway that is responsible for the initiation, and progression of 
tissue fibrosis in SSc. 
